Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Vγ9Vδ2 T-Cell Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BTN2A1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BTN2A1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View BTN2A1 Products |
| Gene Delivery | BTN2A1 Lentivirus Premade Particles Full-length ORF for stable cell line construction and flow cytometry validation. |
View BTN2A1 Products |
| Benchmark Ab | Anti-BTN2A1 Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View BTN2A1 Products |
| Validator | BTN2A1 siRNA Set For target knockdown verification in functional co-culture assays. |
View BTN2A1 Products |
| Related Target A | BTN3A1 Essential co-factor; interacts cooperatively with BTN2A1 to initiate Vγ9Vδ2 T-cell activation. |
View BTN3A1 Products |
| Related Target B | BTN1A1 Structural homolog used for off-target counter-screening to ensure antibody specificity. |
View BTN1A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Primate-Specific Activity Translation | Human and Cynomolgus BTN2A1 ortholog proteins available with >95% purity to verify cross-reactivity |
| Butyrophilin Subfamily Off-Target Risks | Homolog panel (BTN3A1, BTN1A1) strictly verified by sequence and mass spectrometry for counter-screening |
| Lack of Positive Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization |
| Assay Artifacts / Non-specific Binding | Sequence-verified siRNA included for target-specific knockdown validation |
Live BTN2A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BTN2A1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific T-cell engagers. As first-generation therapies targeting the butyrophilin family reach the clinic, the next wave of R&D is targeting the cooperative BTN2A1-BTN3A1 axis to precisely modulate Vγ9Vδ2 T-cell responses in solid tumors and hematological malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonistic mAb | ImCheck Therapeutics | Advanced Solid Tumors, Hematologic Malignancies | Receptor oligomerization assays (Requires high-purity HEK293-expressed ECD-Fc) |
| Bispecific / Gammabody | LAVA Therapeutics | Refractory Multiple Myeloma, Solid Tumors | Dual-targeting binding affinity validation (Requires stable BTN2A1-expressing cell lines via Lentivirus) |
| Antagonistic mAb | Academic / Preclinical Programs | Autoimmune Diseases, Inflammatory Disorders | Ligand-blocking assays (Requires sequence-verified recombinant proteins and benchmark controls) |